Cargando…

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia

BACKGROUND: Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from hematopoietic stem and progenitor cells (HSPCs). Patients with CMML are frequently treated with epigenetic therapeutic approaches, in particular the hypomethylating agents (HMAs), azacitidin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berg, Johannes Lorenz, Perfler, Bianca, Hatzl, Stefan, Mayer, Marie-Christina, Wurm, Sonja, Uhl, Barbara, Reinisch, Andreas, Klymiuk, Ingeborg, Tierling, Sascha, Pregartner, Gudrun, Bachmaier, Gerhard, Berghold, Andrea, Geissler, Klaus, Pichler, Martin, Hoefler, Gerald, Strobl, Herbert, Wölfler, Albert, Sill, Heinz, Zebisch, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789782/ https://www.ncbi.nlm.nih.gov/pubmed/33407852 http://dx.doi.org/10.1186/s13148-020-00979-2

Ejemplares similares

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
por: Hatzl, Stefan, et al.
Publicado: (2020)

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis
por: Caraffini, Veronica, et al.
Publicado: (2020)

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
por: Zebisch, Armin, et al.
Publicado: (2016)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

BRAF(V600E) promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis
por: Sconocchia, Tommaso, et al.
Publicado: (2023)

Multistep pathogenesis of chronic myelomonocytic leukemia in patients
por: Geissler, Klaus, et al.
Publicado: (2022)

TNFα Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBPα
por: Anirudh, Subramanian, et al.
Publicado: (2020)

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
por: Daga, Shruti, et al.
Publicado: (2019)

Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing
por: Kashofer, Karl, et al.
Publicado: (2017)

Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia
por: Machherndl‐Spandl, Sigrid, et al.
Publicado: (2021)

Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia
por: Geissler, Klaus, et al.
Publicado: (2020)

Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy
por: Niscola, Pasquale, et al.
Publicado: (2014)

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
por: Merlevede, Jane, et al.
Publicado: (2016)

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
por: Duchmann, Matthieu, et al.
Publicado: (2018)

Ongoing Clonal Evolution in Chronic Myelomonocytic Leukemia on Hypomethylating Agents: A Computational Perspective
por: Than, Hein, et al.
Publicado: (2018)

Quantifying the impact on navigation performance in visually impaired: Auditory information loss versus information gain enabled through electronic travel aids
por: Kreilinger, Alex, et al.
Publicado: (2018)

Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis
por: Zheng, Xinhui, et al.
Publicado: (2022)

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia
por: Huemer, Florian, et al.
Publicado: (2018)

Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival
por: Geissler, Klaus, et al.
Publicado: (2021)

Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia
por: Zack, Marie-Therese, et al.
Publicado: (2022)

Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia
por: Lackner, David, et al.
Publicado: (2022)

How often are interventions in cluster-randomised controlled trials of complex interventions in general practices effective and reasons for potential shortcomings? Protocol and results of a feasibility project for a systematic review
por: Siebenhofer, Andrea, et al.
Publicado: (2016)

Significance of reduced renal function in patients with chronic myelomonocytic leukemia
por: Heschl, Julia, et al.
Publicado: (2022)

Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia
por: Weinfurtner, Christoph, et al.
Publicado: (2022)

Significance of C-reactive protein in patients with chronic myelomonocytic leukemia
por: Liang-Fonseca, Jian, et al.
Publicado: (2022)

Genotypic and phenotypic evolution in a patient with chronic myelomonocytic leukemia
por: Geissler, Klaus, et al.
Publicado: (2019)

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
por: Daga, Shruti, et al.
Publicado: (2020)

Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches
por: Geissler, Klaus
Publicado: (2021)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
por: Duchmann, M, et al.
Publicado: (2017)

Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report
por: Ai, Yuan, et al.
Publicado: (2020)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial
por: Riedl, Jakob M., et al.
Publicado: (2021)

Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients
por: Geissler, Klaus, et al.
Publicado: (2020)

Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions
por: Müller, Marian, et al.
Publicado: (2019)

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities
por: Foßelteder, Johannes, et al.
Publicado: (2023)

Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients
por: Potočnjak, Ines, et al.
Publicado: (2017)

Complications and mortality of cardiovascular emergency admissions during COVID-19 associated restrictive measures
por: Bugger, Heiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1747cuidh0ghe9plsvlg1eo8lo